Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 10 director nominees elected through the 2027 annual meeting, preserving board continuity.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All 10 director nominees elected through the 2027 annual meeting, preserving board continuity
- Director support varied from 87.6% for Paul Meister to 99.5% for Gautam Patel, excluding broker non-votes
- Executive compensation received strong advisory approval, with 269,089,785 votes for and 2,577,481 against
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 293,211,820 votes for and 409,435 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.